Founded in 2020, we continue to build a platform-agnostic asset portfolio with high value potential, via partnerships and a proactive asset search function. This enables regular portfolio prioritisation and expansion opportunities which in turn enriches for assets with the highest chance of success.
Our success is underpinned by a team of experts with impressive track records in successful drug commercialisation and a demonstrated ability to pick and prioritise those assets most likely to succeed. A focus on the generation of data for prioritisation decisions is underpinned by a capitally efficient and disciplined programme execution.
We seek to deliver differentiated, impactful treatments for patients, resulting in significant returns for our shareholders.
Our structured, network-led sourcing model identifies overlooked opportunities. We rapidly validate assets, de-risk early, and prepare programs for development.
We source innovative assets via:
The company’s trajectory reflects an effective and proactive approach, delivered at speed, with careful consideration given to the data sets that are created and how results inform decision making. The asset portfolio has been developed and honed by combining deep scientific expertise with real-world commercial acumen.
Cumulus has raised £16.5 million to date and signed strategic collaborations with leading partners like leadXpro and the University of Eastern Finland, to leverage platform technologies and molecular insights unavailable to the Pharma industry at large. This has enabled the development of assets on which key intellectual property filings have been achieved.
The modus operandi has created a risk-optimised pipeline through a disciplined asset curation approach. Further pipeline prioritisation and expansion are facilitated by this approach. Adaptability and staged resource allocation to reach milestones on which key decisions are based have resulted in a portfolio of assets where risk is spread across validated and more novel targets, increasing the chance of success.
The Cumulus vision is to accelerate oncology innovation into real patient impact by continuing to build, prioritise and expand the pipeline – delivering differentiated therapeutics with efficiency, flexibility and strong partnership alignment.
Pre-seed funding secured
Partnership established with leading drug discovery groups in Europe
Asset search identifies key assets and targets of interest for licensing/acquistion and partnering
PARGi programme purchased from Basilea Pharmaceutica (CH)
Follow-on seed funding secured
Collaboration agreement signed with leadXpro to discover modulators of the GPR68 target
IP filed on PARGi program
Collaboration agreement signed with the University of Eastern Finland (FI) to discover small molecule modulators of a novel GPTase target
Several small molecule series (Non-allosteric modulators – NAMs) of GPR68 licensed from leadXpro
IP filed for the GPR68 program
Cumulus reaches 5-year anniversary
Clinic-ready asset classes with clear POC in defined patient subgroup are the subject of a focused asset identification and acquisition effort.